Clinical Trials Browser

Phase 3 × nintedanib × Clear all

NCT02231164 2025-02-13

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

Phase 3 Terminated

12 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT00805194 2018-12-05

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Phase 3 Completed

1,314 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT01015118 2017-12-07

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Phase 3 Completed

1,366 enrolled 17 charts

Ovarian Neoplasms, Peritoneal Neoplasms

NCT02149108 2017-07-21

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Phase 3 Completed

768 enrolled 10 charts

Gastrointestinal

Colorectal Neoplasms

NCT00806819 2017-02-02

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Phase 3 Completed

718 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung